SGP

SpyGlass Pharma, Inc. (SGP) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company developing long-acting, sustained drug delivery systems for chronic eye conditions. The company's lead product candidate is the Bimatoprost Drug Pad-IOL System (BIM-IOL System), designed to treat glaucoma during cataract surgery. This report covers the quarterly period ended June 30, 2026. The company completed its Initial Public Offering (IPO) in February 2026, raising approximately $172.5 million in gross proceeds. As of the reporting date, the company has no revenue-generating activities and remains in the clinical development phase.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Growth: Total operating expenses increased by 136% for the three months ended June 30, 2026, compared to the same period in 2025. General and Administrative (G&A) expenses surged 461% (from $2.0 million to $11.0 million), driven by increased headcount and legal/professional services associated with public company compliance. Research and Development (R&D) expenses increased 49% (from $7.3 million to $10.9 million) due to Phase 3 trial enrollment and headcount expansion.
• Capital Structure: In February 2026, the company completed its IPO, converting all outstanding redeemable convertible preferred stock into common stock. This resulted in a significant increase in cash and cash equivalents from $96.4 million at year-end 2025 to $223.1 million at June 30, 2026.
• Interest Income: Interest income increased significantly to $2.1 million for the quarter (up 238% year-over-year) due to higher cash balances and prevailing interest rates.

Guidance, Outlook, and Risks

• Clinical Outlook: The company initiated two registrational Phase 3 trials for the BIM-IOL System in July 2025, expecting to complete enrollment in 2027. A New Drug Application (NDA) is planned for submission in 2028, pending successful results.
• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($234.2 million) are sufficient to fund operations through 2028.
• Internal Controls: The company identified a material weakness in its internal control over financial reporting. Deficiencies include insufficient personnel with technical knowledge, lack of effective risk assessment, and inadequate segregation of duties. Remediation efforts are underway, including hiring additional accounting staff.
• Legal Proceedings: The company is a defendant in a lawsuit filed by Glaukos Corporation alleging trade secret misappropriation. The company denies the allegations and has filed counterclaims. No accrual has been recorded as a loss is not currently deemed probable.
• Regulatory Risks: Success depends on FDA approval, which is not guaranteed. The company relies on the Section 505(b)(2) regulatory pathway, which carries specific risks regarding data reliance and patent litigation.

Investor Verification Checklist

• Phase 3 Enrollment: Verify the progress and patient enrollment rates of the two registrational Phase 3 trials initiated in July 2025.
• Internal Control Remediation: Monitor the company's progress in remediating the material weakness in internal controls to ensure accurate future financial reporting.
• Legal Status: Track developments in the Glaukos Corporation litigation, including potential settlements or court rulings that could impact operations or finances.
• Burn Rate: Assess the sustainability of the current cash burn rate (~$28.4 million in operating cash outflow for the six-month period) against the projected runway through 2028.
• Intellectual Property: Review the status of the license agreement with the University of Colorado and any potential patent challenges regarding the bimatoprost API or delivery mechanism.